ENGN vs. VREX, ORIC, LYEL, NVAX, SIBN, PHAR, ZYME, CSTL, FLGT, and QTRX
Should you be buying enGene stock or one of its competitors? The main competitors of enGene include Varex Imaging (VREX), ORIC Pharmaceuticals (ORIC), Lyell Immunopharma (LYEL), Novavax (NVAX), SI-BONE (SIBN), Pharming Group (PHAR), Zymeworks (ZYME), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), and Quanterix (QTRX). These companies are all part of the "medical" sector.
Varex Imaging (NASDAQ:VREX) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation.
64.2% of enGene shares are owned by institutional investors. 5.2% of Varex Imaging shares are owned by insiders. Comparatively, 13.7% of enGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Varex Imaging has higher revenue and earnings than enGene.
Varex Imaging received 224 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 63.46% of users gave Varex Imaging an outperform vote.
In the previous week, enGene had 37 more articles in the media than Varex Imaging. MarketBeat recorded 39 mentions for enGene and 2 mentions for Varex Imaging. enGene's average media sentiment score of 1.12 beat Varex Imaging's score of 0.14 indicating that Varex Imaging is being referred to more favorably in the media.
Varex Imaging has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, enGene has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500.
Varex Imaging has a net margin of 4.90% compared to Varex Imaging's net margin of 0.00%. enGene's return on equity of 8.26% beat Varex Imaging's return on equity.
Varex Imaging presently has a consensus price target of $27.00, suggesting a potential upside of 73.41%. enGene has a consensus price target of $34.40, suggesting a potential upside of 141.23%. Given Varex Imaging's higher possible upside, analysts plainly believe enGene is more favorable than Varex Imaging.
Summary
Varex Imaging beats enGene on 8 of the 14 factors compared between the two stocks.
Get enGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
